Abstract
Purpose. Aluminum sucrose octasulfate (SOS) is used clinically to prevent ulcers. Under physiologic conditions, the sodium salt of this drug can be formed. Our objective was to determine whether sodium SOS was absorbed when administered orally. In addition to furthering our understanding of aluminum SOS, this study also aimed to clarify how other polyanionic drugs, such as heparin and low-molecular-weight heparins, are absorbed.
Methods. [14C]-labeled and cold sodium SOS (60 mg/kg) were given to rats by stomach tube. Radioactivity was counted in gut tissue, gut washes, and nongut tissue (i.e., lung, liver, kidney, spleen, endothelial, and plasma samples) at 3 min, 6 min, 15 min, 30 min, 60 min, 4 h, and 24 h, and in urine and feces accumulated over 4 h and 24 h.
Results. Peak radioactivity was found in the tissue and washes of the stomach, ileum, and colon at 6 min, 60 min, and 4 h, respectively, showing progression through the gut. Gut recovery accounted for 84% of the dose at 6 min but only 12% of the dose at 24 h, including counts from feces. Radioactivity was recovered from nongut tissue (averaging 8.6% of the dose) and accumulated urine (18% of the dose at 24 h). When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).
Conclusions. Results indicate that sodium SOS is absorbed, agreeing with previous studies demonstrating the oral absorption of other sulfated polyanions. Endothelial concentrations must be considered when assessing the pharmacokinetics of these compounds. The measured plasma drug concentrations reflect the much greater amounts of drug residing with the endothelium.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
J. L. DePriest. Stress ulcer prophylaxis: Do critically ill patients need it? Postgrad. Med. 98:159–168 (1995).
S. A. Ziller and J. C. Netchvolodoff. Uncomplicated peptic ulcer disease: An overview of formation and treatment principles. Postgrad. Med. 93:126–140 (1993).
J. Folkman, S. Szabo, M. Stovroff, P. Mcneil, W. Li, and Y. Shing. Duodenal ulcer: Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Surg. 214:414–425 (1991).
S. Szabo, P. Vattay, E. Scarbrough, and J. Folkman. Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. Am. J. Med. 91:158S–160S (1991).
O. Iqbal, S. Aziz, D. Hoppenstead, S. Ahmad, J. Walenga, M. Bakhos, and J. Fareed. Emerging anticoagulant and thrombolytic drugs. Emerging Drugs 6:111–135 (2001).
K. J. Lorentsen, C. W. Hendrix, J. M. Collins, D. M. Kornhauser, B. G. Petty, R. W. Klecker, C. Flexner, R. H. Eckel, and P. S. Lietman. Dextran sulfate is poorly absorbed after oral administration. Ann. Intern. Med. 111:561–566 (1989).
R. A. Faaij, N. Srivastava, J. M. van-Griensven, R. C. Schoemaker, C. Kluft, J. Burggraaf, and A. F. Cohen. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. Eur. J. Clin. Pharmacol. 54:929–935 (1999).
K. Salartash, M. Lepore, M. D. Gonze, B. A. Leone, R. Baughman, S. W. Charles, J. C. Bowen, and S. R. Money. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann. Surg. 231:789–794 (2000).
L. B. Jaques, L. M. Hiebert, and S. M. Wice. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J. Lab. Clin. Med. 117:122–130 (1991).
L. M. Hiebert, S. M. Wice, T. Ping, D. Herr, and V. Laux. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Thromb. Haemost. 85:114–118 (2001).
F. A. Ofosu. Pharmacological actions of sulodexide. Semin. Thromb. Hemost. 24:127–138 (1998).
J. C. Nickel, B. Johnston, J. Downey, J. Barkin, P. Pommerville, M. Gregoire, and E. Ramsey. Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): A prospective multicenter clinical trial. Urology 56:413–417 (2000).
L. M. Hiebert, S. M. Wice, L. B. Jaques, K. E. Williams, and J. M. Conly. Orally administered dextran sulfate is absorbed in HIVpositive individuals. J. Lab. Clin. Med. 133:161–170 (1999).
L. M. Hiebert, S. M. Wice, N. M. McDuffie, and L. B. Jaques. The heparin target organ-the endothelium: Studies in a rat model. Q. J. Med. 86:341–348 (1993).
L. M. Hiebert, S. M. Wice, T. Ping, R. E. Hileman, I. Capila, and R. J. Linhardt. Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route. Can. J. Physiol. Pharmacol. 78:307–320 (2000).
L. M. Hiebert and L. B. Jaques. Heparin uptake on endothelium. Artery. 2:26–37 (1976).
L. B. Jaques, S. M. Wice, and L. M. Hiebert. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. J. Lab. Clin. Med. 115:422–432 (1990).
C. A. Keele and E. Neil. Samson Wright's Applied Physiology, Oxford University Press, London, 1971.
P. L. Altman and D. S. Ditmer. Biology Data Book Federation of American Societies for Experimental Biology, Washington, DC, 1964.
L. M. Hiebert, S. M. Wice, and L. B. Jaques. Antithrombotic activity of oral unfractionated heparin. J. Cardiovasc. Pharmacol. 28:26–29 (1996).
M. Lunetta and T. Salanitri. Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. J. Intern. Med. Res. 20:45–53 (1992).
S. O. Canapp, R. M. McLaughlin, J. J. Hoskinson, J. K. Roush, and M. D. Butine. Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate. Am. J. Vet. Res. 60:1552–1557 (1999).
L. Bucsi and G. Poor. Efficacy and tolerability of oral chondrotin sulfate as a symtomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 6:31–36 (1998).
L. M. Hiebert, T. Ping, and S. M. Wice. Antithrombotic activity of orally administered low molecular weight heparin (logiparin) in a rat model. Haemostasis 30:196–203 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hiebert, L.M., Wice, S.M., Ping, T. et al. Tissue Distribution of [14C]Sucrose Octasulfate following Oral Administration to Rats. Pharm Res 19, 838–844 (2002). https://doi.org/10.1023/A:1016161001013
Issue Date:
DOI: https://doi.org/10.1023/A:1016161001013